primary prevention of coeliac disease - Associazione Italiana ...

More documents

Recommendations

Info

10 THE BASIS OF COELIAC DISEASE glutamic acid decarboxylase. J Immunol 1996; 156: 2171-7. 31. Lee KH, Wucherpfennig KW, Wiley DC. Structure of a human insulin peptide-HLA- DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001; 2: 501-7. 32. Lundin KEA, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O et al. Gliadinspecific, HLA-DQa1*0501,b1*0201. restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993; 178: 187-96. 33. Lundin KEA, Gjertsen HA, Scott H, Sollid LM, Thorsby E. Function of DQ2 and DQ8 as HLA susceptibility molecules in celiac disease. Hum Immunol 1994; 41: 24-7. 34. Shewry PR, Tatham AS, Kasarda DD. Cereal proteins and coeliac disease. In: Marsh M, editor. Coeliac disease. Oxford: Blackwell Scientific Publications, 1992: 305-48. 35. Lundin KEA, Sollid LM, Norén O, Anthonsen D, Molberg Ø, Thorsby E et al. Heterogenous reactivity patterns of HLA-DQ-restricted small intestinal T-cell clones from patients with celiac disease. Gastroenterology 1997; 112: 752-9. 36. Sjöström H, Lundin KEA, Molberg Ø, Körner R, McAdam SN, Anthonsen D et al. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 1998; 48: 111-5. 37. van de Wal Y, Kooy YM, van Veelen PA, Peña SA, Mearin LM, Molberg Ø et al. Small intestinal T cells of celiac disease patients recognize a natural pepsin fragment of gliadin. Proc Natl Acad Sci U S A 1998; 95: 10050-4. 38. van de Wal Y, Kooy YM, van Veelen P, Vader W, August SA, Drijfhout JW et al. Glutenin is involved in the gluten-driven mucosal T cell response. Eur J Immunol 1999; 29: 3133-9. 39. Molberg Ø, McAdam SN, Körner R, Quarsten H, Kristiansen C, Madsen L et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells. Nat Med 1998; 4: 713-7. 40. van de Wal Y, Kooy Y, van Veelen P, Peña S, Mearin L, Papadopoulos G et al. Selective deamidation by tissue transglutaminase strongly enhances gliadinspecific T cell reactivity. J Immunol 1998; 161: 1585-8. 41. Bruce SE, Bjarnason I, Peters TJ. Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. Clin Sci 1985; 68: 573-9. 42. Aeschlimann D, Paulsson M. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost 1994; 71: 402-15. 43. Folk JE. Mechanism and basis for specificity of transglutaminase-catalyzed e-g- (glutamyl) lysine bond formation. Adv Enzymol Relat Areas Mol Biol 1983; 54:1- 56. 44. Arentz-Hansen H, Korner R, Molberg O, Quarsten H, Vader W, Kooy YM et al. The intestinal T cell response to a-gliadin in adult celiac disease is focused on a single deamidated glutamine targeted by tissue transglutaminase. J Exp Med 2000; 191: 603-12. 45. Quarsten H, Molberg Ø, Fugger L, McAdam SN, Sollid LM. HLA binding and T cell recognition of a tissue transglutaminase - modified gliadin epitope. Eur J Immunol 1999; 29: 2506-14.
THE BASIS OF COELIAC DISEASE 11 46. Molberg Ø, McAdam S, Lundin KEA, Kristiansen C, Arentz-Hansen H, Kett K et al. T cells from celiac disease lesions recognize gliadin epitopes deamidated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001; 31: 1317-23. 47. Komagata Y, Weiner HL. Oral tolerance. Rev Immunogenet 2000; 2: 61-73. 48. Maiuri L, Picarelli A, Boirivant M, Coletta S, Mazzilli MC, De Vincenzi M et al. Definition of the initial immunologic modifications upon in vitro gliadin challenge in the small intestine of celiac patients. Gastroenterology 1996; 110: 1368-78. 49. Maiuri L, Auricchio S, Coletta S, De Marco G, Picarelli A, Di Tola M et al. Blockage of T-cell costimulation inhibits T-cell action in celiac disease. Gastroenterology 1998; 115: 564-72. 50. Bajaj-Elliott M, Poulsom R, Pender SL, Wathen NC, MacDonald TT. Interactions between stromal cell--derived keratinocyte growth factor and epithelial transforming growth factor in immune-mediated crypt cell hyperplasia. J Clin Invest 1998; 102: 1473-80. 51. Deem RL, Shanahan F, Targan SR. Triggered human mucosal T cells release tumour necrosis factor - alpha and interferon-gamma which kill human colonic epithelial cells. Clin Exp Immunol 1991; 83: 79-84. 52. Groh V, Steinle A, Bauer S, Spies T. Recognition of stress-induced MHC molecules by intestinal epithelial gdT cells. Science 1998; 279: 1737-40. 53. Daum S, Bauer U, Foss HD, Schuppan D, Stein H, Riecken EO et al. Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 1999; 44: 17-25. 54. Mäki M. The humoral immune system in coeliac disease. In: Howdle PD, editor. Coeliac disease. London: Bailliére Tindall, 1995: 231-49. 55. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797-801. 56. Halttunen T, Mäki M. Serum immunoglobulin A from patients with celiac disease inhibits human T84 intestinal crypt epithelial cell differentiation. Gastroenterology 1999; 116: 566-72. 57. Sollid LM, Scott H. New tool to predict celiac disease on its way to the clinics. Gastroenterology 1998; 115: 1584-6. 58. Appel H, Seth NP, Gauthier L, Wucherpfennig KW. Anergy induction by dimeric TCR ligands. J Immunol 2001; 166: 5279-85.
Page 1: Perspectives on Coeliac Disease Vol
Page 4: The AIC Meeting was held in the Aul
Page 8 and 9: Italian Coeliac Society, Via Picott
Page 11 and 12: Preface Coeliac disease (CD) is a u
Page 13: Contents Current understanding of t
Page 16 and 17: 2 THE BASIS OF COELIAC DISEASE hapl
Page 18 and 19: 4 THE BASIS OF COELIAC DISEASE 1 pr
Page 20 and 21: 6 THE BASIS OF COELIAC DISEASE spre
Page 22 and 23: 8 THE BASIS OF COELIAC DISEASE Ackn
Page 27 and 28: Catassi C, Fasano A, Corazza GR (ed
Page 29: T CELL RESPONSES TO GLUTEN PEPTIDES
Page 32 and 33: 18 A DOMINANT EPITOPE IN GLUTEN PEP
Page 42 and 43: 28 ROLE OF A-GLIADIN 31-49 PEPTIDE
Page 45 and 46: Catassi C, Fasano A, Corazza GR (ed
Page 47 and 48: COELIAC DISEASE IN THE SAHARAWI 33
Page 55: COELIAC DISEASE IN THE SAHARAWI 41
Page 58 and 59: 44 INFANT FEEDING PRACTICES AND COE
Page 66 and 67: Age (years) 52 INFANT FEEDING PRACT
Page 74 and 75:
60 INFANT FEEDING PRACTICES AND COE
Page 76 and 77:
62 MECHANISMS OF ORAL TOLERANCE the
Page 78 and 79:
64 MECHANISMS OF ORAL TOLERANCE pot
Page 80 and 81:
66 MECHANISMS OF ORAL TOLERANCE Epi
Page 82 and 83:
68 MECHANISMS OF ORAL TOLERANCE typ
Page 84 and 85:
70 MECHANISMS OF ORAL TOLERANCE 51
Page 86 and 87:
72 MECHANISMS OF ORAL TOLERANCE 23.
Page 89 and 90:
Catassi C, Fasano A, Corazza GR (ed
Page 91 and 92:
GENETICALLY DETOXIFIED GRAINS 77 to
Page 93 and 94:
• • GENETICALLY DETOXIFIED GRAI
Page 95 and 96:
GENETICALLY DETOXIFIED GRAINS 81 3.
Page 97 and 98:
Page 99 and 100:
IMMUNOTHERAPY OF COELIAC DISEASE 85
Page 101 and 102:
IMMUNOTHERAPY OF COELIAC DISEASE 87
Page 103 and 104:
Page 105 and 106:
RECENT ADVANCES ON GLUTEN TOXICITY
Page 107 and 108:
Index A Antiendomysium antibodies (
Page 109:
INDEX 95 W Wheat, 7, 23, 27, 31, 53
show all

primary prevention of coeliac disease - Associazione Italiana ...

Create successful ePaper yourself

Delete template?

Save as template?